Corvus cuts ATM program ceiling from $90M to $8.2M; nearly all capacity used

Corvus Pharmaceuticals, Inc.

Amendment reduces aggregate offering price under Jefferies ATM from $90M to $8.2M.
Approximately $8.1M of shares sold to date, leaving ~$100,000 remaining availability.
Program originally entered into on March 28, 2023; amendment dated May 1, 2024.

item 8.01 item 9.01

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-127611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.